ASCO 2023 Prostate Cancer

Viewing 1-20 of 84 articles

ASCO 2023: Timing of PARP Inhibition for Prostate Cancer with Defects in Homologous Recombination Repair

ASCO 2023: A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer

ASCO 2023: Exercise to Enhance Cardiovascular Health Among Black Patients with Prostate Cancer with Androgen Deprivation Therapy: The POWER Trial

ASCO 2023: Technology-Enhanced Acceleration of Germline Evaluation for Therapy (TARGET): Results of a Randomized Controlled Trial of a Pretest Patient-Driven Webtool vs. Genetic Counseling for Prostate Cancer Germline Testing

ASCO 2023: Sequential Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Assessed by PET-Based Imaging

ASCO 2023: Prevalence of Mismatch Repair Deficiency in a Large Prospective Prostate Cancer Cohort

ASCO 2023: Helping Our Elders Survive and Thrive with Prostate Cancer: Known and Novel Intervention Strategies

ASCO 2023: Applying Risk/Benefit Considerations for Elder Patients to Current Treatment Advances in Prostate Cancer

ASCO 2023: Digital Histopathology-Based Multimodal Artificial Intelligence Scores Predict Risk of Progression in a Randomized Phase III Trial in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

ASCO 2023: When More Is More: Treatment Intensification for Hormone-Sensitive Prostate Cancer

ASCO 2023: When Less Is More: Decreasing Exposure to Systemic Therapy for Hormone-Sensitive Prostate Cancer

ASCO 2023: Management of Prostate Cancer in Older Adults: Assessment and Decision Tools for Balancing Survival and Quality of Life

ASCO 2023: Non-Interventional REASSURE Study: Assessing the Real-World Safety and Effectiveness of Radium-223 in US Patients with mCRPC

ASCO 2023: AI-Enabled Analysis of H&E-Stained Prostate Cancer Tissue Images: Assessing Risk for Metastasis Prior to Apalutamide (APA) Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

ASCO 2023: Impact of Synchronous vs Metachronous Metastasis at Presentation on Survival in Patients with mCRPC Treated with Androgen Receptor Signaling Inhibitors

ASCO 2023: Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular Depot Injection of Abiraterone Decanoate, in Patients with Advanced Prostate Cancer

ASCO 2023: Talazoparib + Enzalutamide in mCRPC: Safety Analyses from the Randomized, Placebo-Controlled, Phase 3 TALAPRO-2 Study

ASCO 2023: Association of Plant-Based Diet Index with Quality of Life in Patients with Prostate Cancer

ASCO 2023: PROPELLER: 64Cu-SAR-bisPSMA PET Imaging in Patients with Confirmed Prostate Cancer

ASCO 2023: Concurrent Chemo-Hormonal Therapy of Enzalutamide and Cabazitaxel in Patients with mCRPC: Final Analysis of ORR, rPFS, and OS

1
2
3
4
5